We screened antiviral activities of plants and herbs, EPA-W (the water extract of Echinacea purpurea aerial component) and SMf-2-E (the ethanol extract of fresh Salvia miltiorrhiza) were the best (EPA-W, for adenovirus serotype 3 with IC50 of 4.6 μg/ml and SI>600; SMf-2-E, for EV71 with IC50 8.3 μg/ml and SI: >100) to make the antiviral pharmaceutical combination, which has been filed for Taiwan patent.

1.抗病毒醫藥組合物提供腸病毒71型與腺病毒發展植物新藥的契機
2.機能性配方提供多元性健康食品與保健市場的多重開發機會

Innovation: This antiviral pharmaceutical combination has antiviral activity against adenovirus and EV71.
Professional: The component plants are planted by GAP.
Potential: Since adenoviruses and EV71 are common, the market need of such antiviral products is big.
Application: According to the Taiwan FDA, its component plants have been edible for years, it can be feasibly applied to make antiviral products.